Celluminova

Celluminova is a pioneering biotechnology research company dedicated to the identification and targeting of cancer stem cells, with an initial focus on malignant gliomas, aggressive brain tumors. Celluminova is committed to developing innovative solutions that address the challenges of tumor recurrence and resistance to conventional therapies. Recognizing the critical role of glioma stem cells in driving tumor progression, Celluminova has developed a groundbreaking molecule specifically designed to target these cells.

Celluminova's patented compound, p-HTMI, represents a significant advancement in the field of neurosurgery. This fluorescent molecule illuminates glioma stem cells, enabling neurosurgeons to distinguish between healthy and cancerous tissue with exceptional speed and precision during brain surgery. Located in Linköping, SE, Celluminova is dedicated to improving patient outcomes through the precise detection and removal of cancerous cells, potentially leading to enhanced survival rates for patients battling aggressive brain tumors.

With a strong commitment to translating research into tangible clinical benefits, Celluminova is poised to revolutionize the treatment landscape for malignant gliomas. The company's innovative approach holds immense promise for improving the lives of patients and transforming the future of cancer therapy. We invite the management team at Celluminova to create a customized and exclusive company showcase and product listing on our platform to further highlight your groundbreaking work.